Comparative potency of formulations of mometasone furoate in terms of inhibition of 'PIRHR' in the forearm skin of normal human subjects measured with laser doppler velocimetry

Indian Journal of Dermatology, Venereology and Leprology

Volumn 71, Issue 3, 2005, Pages 170-174

  Kulhalli, Prabhakar ^a   Chevli, Tejal ^a   Karnik, Rupal ^a   Sheth, Manish ^b   Mulgaonkar, Nitin ^b  

^a Zandu Pharmaceutical Works Ltd   (India)

^b Fulford (India) Limited   (India)

Author keywords

Inhibition of PIRHR; LDV; Mometasone; Potency; Topical formulations

Indexed keywords

GLUCOCORTICOID; MOMETASONE FUROATE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG POTENCY; FEMALE; FOREARM; HUMAN; HYPEREMIA; ISCHEMIA; LASER DOPPLER FLOWMETRY; MALE; NORMAL HUMAN; PROTECTIVE CLOTHING; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN; SKIN BLOOD FLOW;

EID: 21244480550     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.16231     Document Type: Article

References (15)

1. Miller JA, Munro DD. Topical corticosteroids: Clinical pharmacology and therapeutic use. Drugs 1980;19:119-34.
2. Poelman MC, Leveque JL, Le Gall F. Objective determination of the bioavailability of dermacorticoids-influence of the formulation. Br J Dermatol 1984;111:158-62.
3. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: Clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002;3:47-58.
4. Kreilgaard M, Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF. Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. Pharm Res 2001;18:593-9.
5. Fang JY, Shen KL, Huang YB, Wu PC, Tsai YH. Evaluation of topical application of clobetasol 17-propionate from various cream bases. Drug Dev Ind Pharm 1999;25:7-14.
6. Gao HY, Li Wan Po A. Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity? Eur J Clin Pharmacol 1994;46:71-5.
7. Olsen EA. A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay. Arch Dermatol 1991;127:197-201.
8. Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 1987;123:1312-4.
9. Sequira J, Berardi M, Chan TM, Letarte J, Malchow R, Pramanick B, et al. Assessing equivalence of innovator and generic formulations of betamethasone dipropionate cream and ointment. Clin Ther 1991;13:687-94.
10. Stoughton RB, Wullich K. The same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity? Arch Dermatol 1989;125:1509-11.
11. Jackson DB, Thompson C, McCormack JR, Guin JD. Bioequivalence (bioavailability) of generic topical corticosteroids. J Am Acad Dermatol 1989;20:791-6.
12. Barry BW, Woodford R. Proprietary hydrocortisone creams. Vasoconstrictor activities and bio-availabilities of six preparations. Br J Dermatol 1976;95:423-5.
13. Singh GJ, Adams WP, Lesko LJ, Shah VP, Molzon JA, Williams RL, et al. Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clin Pharmacol Ther 1999;66:346-57.
14. Bisgaard H, Kristensen JK, Sondergaard J. A new technique for ranking vascular corticosteroid effects in humans using laser-doppler velocimetry. J Invest Dermatol 1986;86:275-8.
15. Mulekar SV, Mahajani SS, Kulhalli PM, Bakhle DS, Menon SS. Study of topical anti-inflammatory potency and clinical efficacy of formulations of Mometasone and Betamethasone by cutaneous blood flow measurements in psoriatic patients using laser-doppler velocimetry. Indian J Dermatol Venereol Leprol 1997;42:1-8.